The highest approved dose of Wegovy is now 7.2 mg, sold as Wegovy HD. The FDA approved it in March 2026, and Novo Nordisk launched it in April 2026, making it the strongest Wegovy injection available. It sits above the long-standing 2.4 mg maintenance dose and is meant for adults who have tolerated 2.4 mg for at least four weeks and need additional weight loss. In its main trial, Wegovy HD produced about 20.7% average weight loss, compared with about 17.5% on the 2.4 mg dose. Here’s what the higher dose involves and who it’s for.<\/p>\n
Wegovy HD is a 7.2 mg once-weekly injection of semaglutide, the same active ingredient as standard Wegovy, at a higher strength. The FDA approved it on March 19, 2026, under an accelerated review program, and it became available in April 2026 through major pharmacies and telehealth channels. It joins the existing Wegovy lineup, which includes the 1.7 mg and 2.4 mg injections and the 25 mg daily pill.<\/p>\n
Wegovy HD isn’t a starting dose. It’s a step-up option for people who have already tolerated 2.4 mg for at least four weeks and, with their provider, decide that more weight loss is clinically needed. That gradual path still matters: jumping ahead without building tolerance raises the risk of significant gastrointestinal side effects.<\/p>\n
The approval is based on the STEP UP trial, a 72-week study of 1,407 adults with obesity (without diabetes) comparing 7.2 mg, 2.4 mg, and placebo. On the 7.2 mg dose, participants lost about 20.7% of their body weight on average, versus about 17.5% on 2.4 mg and 2.4% on placebo. Roughly one in three people on 7.2 mg lost 25% or more of their body weight, a level often associated with bariatric surgery. A companion trial in people with obesity and type 2 diabetes (STEP UP T2D) showed about 14.1% weight loss on the higher dose.<\/p>\n
So the step from 2.4 mg to 7.2 mg added roughly 3 percentage points of average weight loss in the obesity trial. That’s a meaningful gain for some people, but not a dramatic leap, which is part of why the higher dose is positioned as a targeted step-up rather than a new default.<\/p>\n
| <\/th>\n | Wegovy 2.4 mg<\/th>\n | Wegovy HD 7.2 mg<\/th>\n<\/tr>\n<\/thead>\n |
|---|---|---|
| Status<\/td>\n | Approved<\/td>\n | Approved (March 2026)<\/td>\n<\/tr>\n |
| Dosing<\/td>\n | Weekly injection<\/td>\n | Weekly injection<\/td>\n<\/tr>\n |
| Average weight loss<\/td>\n | ~17.5% (STEP UP)<\/td>\n | ~20.7% (STEP UP)<\/td>\n<\/tr>\n |
| Lost 25% or more<\/td>\n | Fewer<\/td>\n | ~1 in 3<\/td>\n<\/tr>\n |
| Who it’s for<\/td>\n | Standard maintenance<\/td>\n | Step-up after tolerating 2.4 mg for 4+ weeks<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\nSide Effects of the Higher Dose<\/h3>\nWegovy HD’s side effects are largely the familiar GLP-1 ones: nausea, vomiting, diarrhea, constipation, and abdominal pain, usually mild to moderate and more common during dose increases. One difference stood out in trials. Altered skin sensation (described as sensitivity, tingling, or burning, known medically as dysesthesia) was more common on 7.2 mg, reported by about 22% of participants, compared with about 6% on 2.4 mg. These reports were generally mild and often resolved on their own or with a dose reduction, and the FDA has said it is continuing to look into this reaction.<\/p>\n As with all semaglutide products, Wegovy carries a boxed warning about a potential risk of thyroid C-cell tumors based on animal studies. It shouldn’t be used by people with a personal or family history of medullary thyroid carcinoma or MEN 2 (a genetic condition), and serious risks can include pancreatitis and gallbladder problems.<\/p>\n Should You Move Up to 7.2 mg?<\/h3>\nHigher isn’t automatically better. The 2.4 mg dose already produces substantial weight loss for many people, and moving up generally makes sense only if you’ve plateaued or haven’t reached your goal and you’re tolerating 2.4 mg well. The trade-off is a somewhat higher chance of side effects in exchange for additional weight loss.<\/p>\n This is a decision to make with your provider, who can weigh your progress, your tolerance, and your goals. You should never increase your dose on your own; the step-up requires a prescription and medical guidance, just like every earlier stage of treatment.<\/p>\n How to Get Started<\/h3>\nIf you’re considering Wegovy, or wondering whether a higher dose fits your situation later on, a licensed provider can help you find the right starting dose<\/a> and a safe path toward your maintenance level. Knowing what the first month typically looks like<\/a> and what Wegovy costs without insurance<\/a> can also help you plan.<\/p>\n |